GT200600217A - Proceso para la sintesis de compuestos organicos - Google Patents

Proceso para la sintesis de compuestos organicos

Info

Publication number
GT200600217A
GT200600217A GT200600217A GT200600217A GT200600217A GT 200600217 A GT200600217 A GT 200600217A GT 200600217 A GT200600217 A GT 200600217A GT 200600217 A GT200600217 A GT 200600217A GT 200600217 A GT200600217 A GT 200600217A
Authority
GT
Guatemala
Prior art keywords
synthesis
organic compounds
useful
compounds
thyrosines
Prior art date
Application number
GT200600217A
Other languages
English (en)
Spanish (es)
Inventor
Joseph Mckenna
Wen-Chung Shieh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200600217A publication Critical patent/GT200600217A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Steroid Compounds (AREA)
GT200600217A 2005-06-09 2006-05-24 Proceso para la sintesis de compuestos organicos GT200600217A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68897705P 2005-06-09 2005-06-09
US70559005P 2005-08-04 2005-08-04

Publications (1)

Publication Number Publication Date
GT200600217A true GT200600217A (es) 2007-03-28

Family

ID=37091153

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600217A GT200600217A (es) 2005-06-09 2006-05-24 Proceso para la sintesis de compuestos organicos

Country Status (31)

Country Link
US (2) US8124763B2 (enExample)
EP (1) EP1924574B1 (enExample)
JP (1) JP5118024B2 (enExample)
KR (3) KR20120066067A (enExample)
AR (1) AR053890A1 (enExample)
AT (1) ATE487709T1 (enExample)
AU (1) AU2006258051B2 (enExample)
BR (1) BRPI0611663A2 (enExample)
CA (1) CA2610105C (enExample)
CY (1) CY1111428T1 (enExample)
DE (1) DE602006018156D1 (enExample)
DK (1) DK1924574T3 (enExample)
EC (1) ECSP077982A (enExample)
EG (1) EG25039A (enExample)
GT (1) GT200600217A (enExample)
IL (1) IL187421A (enExample)
JO (1) JO2636B1 (enExample)
MA (1) MA29599B1 (enExample)
MX (1) MX2007015423A (enExample)
MY (1) MY147436A (enExample)
NO (1) NO340743B1 (enExample)
NZ (1) NZ563740A (enExample)
PE (1) PE20070015A1 (enExample)
PL (1) PL1924574T3 (enExample)
PT (1) PT1924574E (enExample)
RU (1) RU2444520C2 (enExample)
SA (1) SA06270147B1 (enExample)
SI (1) SI1924574T1 (enExample)
TN (1) TNSN07463A1 (enExample)
TW (1) TWI430999B (enExample)
WO (1) WO2006135641A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
TWI433677B (zh) 2007-06-04 2014-04-11 Avila Therapeutics Inc 雜環化合物及其用途
US20100016590A1 (en) * 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
EP2530081A3 (en) 2008-11-05 2013-04-10 Teva Pharmaceutical Industries, Ltd. Nilotinib HCI crystalline forms
WO2010060074A1 (en) * 2008-11-24 2010-05-27 Teva Pharmaceutical Industries Ltd. Preparation of nilotinib and intermediates thereof
US20110053968A1 (en) 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
WO2012135651A1 (en) 2011-03-31 2012-10-04 The Procter & Gamble Company Systems, models and methods for identifying and evaluating skin-active agents effective for treating dandruff/seborrheic dermatitis
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
WO2013120852A1 (en) 2012-02-13 2013-08-22 Grindeks, A Joint Stock Company Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
US9920357B2 (en) 2012-06-06 2018-03-20 The Procter & Gamble Company Systems and methods for identifying cosmetic agents for hair/scalp care compositions
WO2015092624A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Nilotinib mono-oxalate and its crystalline form
CN103694176B (zh) 2014-01-07 2015-02-18 苏州立新制药有限公司 尼洛替尼中间体的制备方法
EP3095782A1 (en) 2015-05-18 2016-11-23 Esteve Química, S.A. New method for preparing 3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)benzenamine
EP3749697A4 (en) 2018-02-05 2021-11-03 Bio-Rad Laboratories, Inc. CHROMATOGRAPHY RESIN WITH LIGAND MIXED MODE ANIONIC / HYDROPHOBIC EXCHANGE
EP3806858A4 (en) 2018-06-15 2022-03-09 Handa Pharmaceuticals, Inc. KINA INHIBITOR SALTS AND COMPOSITIONS THEREOF
JP2020007240A (ja) * 2018-07-04 2020-01-16 住友化学株式会社 ベンズアミド化合物の製造方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5136082A (en) * 1990-08-03 1992-08-04 Himont Incorporated Process for preparing organic esters and amides and catalyst system therefor
AU5539294A (en) 1992-12-24 1994-07-19 Hemagen/Pfc Fluorocarbon emulsions
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5597829A (en) 1994-05-09 1997-01-28 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin and methods for uses thereof
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US6323366B1 (en) 1997-07-29 2001-11-27 Massachusetts Institute Of Technology Arylamine synthesis
AR013261A1 (es) 1997-08-01 2000-12-13 Smithkline Beecham Corp Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina
US20030059465A1 (en) 1998-05-11 2003-03-27 Unger Evan C. Stabilized nanoparticle formulations of camptotheca derivatives
US6395916B1 (en) * 1998-07-10 2002-05-28 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
EP1044977B1 (en) 1999-03-09 2002-05-02 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Camptothecin derivatives having antitumor activity
IT1306129B1 (it) 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
DE19926056B4 (de) 1999-06-08 2004-03-25 Gkss-Forschungszentrum Geesthacht Gmbh Einrichtung zur Analyse atomarer und/oder molekularer Elemente mittels wellenlängendispersiver, röntgenspektrometrischer Einrichtungen
GB9918885D0 (en) 1999-08-10 1999-10-13 Pharmacia & Upjohn Spa Pharmaceutical formulations in hydroxypropymethycellulose capsules
GB9925127D0 (en) 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
US20040009229A1 (en) 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
US20020150615A1 (en) 2001-02-12 2002-10-17 Howard Sands Injectable pharmaceutical composition comprising microdroplets of a camptothecin
US6629598B2 (en) 2001-08-10 2003-10-07 Vinod K. Narula Flexible ribbed splint system
US6653319B1 (en) 2001-08-10 2003-11-25 University Of Kentucky Research Foundation Pharmaceutical formulation for poorly water soluble camptothecin analogues
WO2003032906A2 (en) 2001-10-15 2003-04-24 Crititech, Inc. Delivery of poorly soluble drugs
AU2002353118A1 (en) 2001-12-11 2003-07-24 Dor Biopharma, Inc. Lipid particles and suspensions and uses thereof
JP2003267891A (ja) 2002-03-13 2003-09-25 Mitsubishi-Kagaku Foods Corp W/o/w型エマルション製剤
FR2840303B1 (fr) * 2002-05-31 2005-07-15 Rhodia Chimie Sa Procede d'arylation ou de vinylation ou d'alcylynation d'un compose nucleophile
CZ294371B6 (cs) 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
EP1393719A1 (en) 2002-08-23 2004-03-03 Munich Biotech AG Camptothecin-carboxylate formulations
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
JP4426749B2 (ja) 2002-07-11 2010-03-03 株式会社産学連携機構九州 O/w型エマルション製剤
US20040171560A1 (en) 2002-12-23 2004-09-02 Dabur Research Foundation Stabilized pharmaceutical composition
JP2006199590A (ja) 2003-09-04 2006-08-03 Nano Career Kk 水溶性の塩基性薬物内包ナノ粒子含有組成物
CA2543722C (en) 2003-10-29 2011-01-04 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
CA2548078C (en) 2003-12-17 2009-05-12 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of camptothecins and process for making same
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos

Also Published As

Publication number Publication date
RU2444520C2 (ru) 2012-03-10
HK1117524A1 (en) 2009-01-16
AU2006258051A1 (en) 2006-12-21
JP5118024B2 (ja) 2013-01-16
IL187421A (en) 2011-11-30
MX2007015423A (es) 2008-02-21
PL1924574T3 (pl) 2011-04-29
DK1924574T3 (da) 2011-02-14
TNSN07463A1 (en) 2009-03-17
NO340743B1 (no) 2017-06-12
KR20130118394A (ko) 2013-10-29
IL187421A0 (en) 2008-02-09
US8124763B2 (en) 2012-02-28
CY1111428T1 (el) 2015-08-05
SI1924574T1 (sl) 2011-02-28
PT1924574E (pt) 2011-02-08
KR20120066067A (ko) 2012-06-21
TWI430999B (zh) 2014-03-21
EG25039A (en) 2011-07-06
US8946416B2 (en) 2015-02-03
EP1924574B1 (en) 2010-11-10
KR20080022093A (ko) 2008-03-10
MY147436A (en) 2012-12-14
AU2006258051B2 (en) 2010-09-09
US20080188656A1 (en) 2008-08-07
CA2610105C (en) 2014-03-25
JO2636B1 (en) 2012-06-17
ATE487709T1 (de) 2010-11-15
JP2008545786A (ja) 2008-12-18
NO20080157L (no) 2008-01-09
CA2610105A1 (en) 2006-12-21
EP1924574A2 (en) 2008-05-28
SA06270147B1 (ar) 2009-12-22
TW200726756A (en) 2007-07-16
MA29599B1 (fr) 2008-07-01
AR053890A1 (es) 2007-05-23
PE20070015A1 (es) 2007-02-06
ECSP077982A (es) 2008-01-23
NZ563740A (en) 2011-03-31
KR101216249B1 (ko) 2012-12-28
US20120116081A1 (en) 2012-05-10
WO2006135641A2 (en) 2006-12-21
DE602006018156D1 (de) 2010-12-23
BRPI0611663A2 (pt) 2010-09-28
RU2007148231A (ru) 2009-07-20
KR101514593B1 (ko) 2015-04-22
WO2006135641A3 (en) 2007-03-29

Similar Documents

Publication Publication Date Title
GT200600217A (es) Proceso para la sintesis de compuestos organicos
GT200500103A (es) 4-fenilamino-quinazolin-6-il-amidas
GT200700039A (es) Derivados de triazolopirazina
GT200600306A (es) Inhibidores de glutamato agrecanasa
GT200800258A (es) Compuestos de pirrolo-pirimidina y sus usos
GT200500226A (es) Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa
ATE523514T1 (de) Tricyclische triazolische verbindungen
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
GT200500008A (es) Intermediarios de quinolina como inhibidores de receptores de tirosina quinasas y la sintesis de los mismos
CU20110052A7 (es) Compuestos orgánicos
GT200600181A (es) Derivados de amida sustituida y metodos de uso
GT200500208A (es) Indazoles ùtiles para tratar enfermedades cardiovasculares
GT200600246A (es) Formulacion de 1-[(3-hidroxi-adamant-1-ilamino)-acetil]-pirrolidin-2(s)-carbonitrilo de liberacion modificada
GT200800103A (es) 5-aril isoxazolinas para controlar plagas de invertebrados
GT200300087A (es) 2-(2,6-diclorofenil)-diarilimidazoles
GT200500242A (es) Procesos para la preparaciòn de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
PA8809001A1 (es) Compuestos organicos
GT200600167A (es) Derivados de dihidrobenzofurano y usos de los mismos
GT200600430A (es) Compuestos de carboxiamina y metodos de uso de los mismos
PL1891004T3 (pl) Pentafluorosulfanylo-podstawiony związek i jego zastosowanie do wytwarzania środków leczniczych
MX2007014172A (es) Procedimiento para la produccion de 4-bifenililacetidina-2-onas fenolicos.
GT200600030A (es) 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2
GT200600174A (es) Pirrolopiridinas sustituidas, composiciones que las contienen, proceso de fabricacion y utilizacion
ECSP099315A (es) Inhibidores de cinasa
GT200600107A (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos